Giredestrant is a small molecule commercialized by Roche, with a leading Phase III program in Metastatic Breast Cancer;Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 16 clinical trials, of which 5 were completed, 10 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Giredestrant’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Giredestrant is expected to reach an annual total of $534 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Giredestrant Overview
GDC-9545 (RG-6171) is under development for the treatment of solid tumors, estrogen receptor positive and HER2 negative metastatic breast cancer, HER2-positive, estrogen receptor positive locally advanced or metastatic breast cancer, neoadjuvant ER positive breast cancer and endometrial cancer. The drug candidate is administered by the oral route. The drug candidate acts as a selective estrogen receptor degrader (SERD) by targeting the estrogen receptor (ER). The drug candidate is a new molecular entity (NME).
Roche Overview
Roche is a holding company that is involved in the business of offering oncology, immunology, infectious diseases, ophthalmology and neuroscience research services. The company is headquartered in Basel, Basel-Stadt, Switzerland.
The company reported revenues of (Swiss Francs) CHF58,716 million for the fiscal year ended December 2023 (FY2023), a decrease of 7.2% over FY2022. In FY2023, the company’s operating margin was 25.8%, compared to an operating margin of 27.5% in FY2022. In FY2023, the company recorded a net margin of 19.6%, compared to a net margin of 19.6% in FY2022.
For a complete picture of Giredestrant’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.